We are live on ! Find out more
MYGN icon

Myriad Genetics
MYGN

260 hedge funds and large institutions have $2.22B invested in Myriad Genetics in 2018 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 93 increasing their positions, 82 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 23

54% more call options, than puts

Call options by funds: $11.2M | Put options by funds: $7.24M

13% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 82

4% more funds holding

Funds holding: 250 → 260 (+10)

0.08% less ownership

Funds ownership: 107.84% → 107.76% (-0.08%)

13% less capital invested

Capital invested by funds: $2.56B → $2.22B (-$341M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
260
Holders Change
+10
Holders Change %
+4%
% of All Funds
5.96%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
36
Increased
93
Reduced
82
Closed
23
Calls
$11.2M
Puts
$7.24M
Net Calls
+$3.92M
Net Calls Change
+$2.06M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$25M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$18.6M
3
SI
Sensato Investors
California
+$17.5M
4
BlackRock
BlackRock
New York
+$11M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$5.94M

Top Sellers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
-$23.4M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$19.4M
3
BIM
Bogle Investment Management
Massachusetts
-$10.1M
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$9.16M
5
Millennium Management
Millennium Management
New York
-$6.65M
Name Holding Trade Value Shares
Change 		Change in
Stake
CIP
101
Chartwell Investment Partners
Pennsylvania
$1.32M -$2.57M -76,005 -63%
AIA
102
AIMZ Investment Advisors
California
$1.29M – – –
Squarepoint
103
Squarepoint
New York
$1.26M +$594K +17,544 +70%
Fidelity Investments
104
Fidelity Investments
Massachusetts
$1.25M +$5.65K +167 +0.4%
AIG
105
American International Group
New York
$1.23M -$360K -10,653 -20%
3C
106
361 Capital
Colorado
$1.22M +$1.39M +41,222 New
BIM
107
Bogle Investment Management
Massachusetts
$1.21M -$10.1M -297,093 -88%
CM
108
CS McKee
Pennsylvania
$1.2M -$50.8K -1,500 -4%
SO
109
STRS Ohio
Ohio
$1.18M +$105K +3,100 +8%
DekaBank Deutsche Girozentrale
110
DekaBank Deutsche Girozentrale
Germany
$1.16M -$225K -6,642 -15%
Millennium Management
111
Millennium Management
New York
$1.12M -$6.65M -196,624 -84%
First Trust Advisors
112
First Trust Advisors
Illinois
$1.09M +$1.25M +37,011 New
PA
113
Profund Advisors
Maryland
$1.09M +$45.2K +1,336 +4%
TAM
114
Tocqueville Asset Management
New York
$1.04M – – –
USAA
115
United Services Automobile Association
Texas
$1.01M +$247K +7,310 +27%
GAM
116
Gotham Asset Management
New York
$974K -$3.78M -111,800 -77%
LSERS
117
Louisiana State Employees Retirement System
Louisiana
$916K +$40.6K +1,200 +4%
PFM
118
Parsec Financial Management
North Carolina
$902K -$56.9K -1,681 -5%
SSCM
119
Summit Street Capital Management
New York
$889K -$3.86M -114,000 -79%
MIM
120
MetLife Investment Management
New Jersey
$879K – – –
LPIC
121
LeJeune Puetz Investment Counsel
Michigan
$858K – – –
Arrowstreet Capital
122
Arrowstreet Capital
Massachusetts
$835K -$990K -29,252 -51%
Jennison Associates
123
Jennison Associates
New York
$827K +$947K +27,991 New
MERSOM
124
Municipal Employees' Retirement System of Michigan
Michigan
$824K +$67.7K +2,000 +8%
FIM
125
Freedom Investment Management
Connecticut
$801K +$36.6K +1,083 +4%
3 4
5
6 7

MYGN Hedge Fund Activity: Q1 2018 in Review

260 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2018, worth a combined $2.22B — down 13% from $2.56B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new MYGN positions and 23 closed out — a net gain of 13 holders — while 93 added to existing stakes and 82 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $25M. The largest seller was Wells Fargo, cutting an estimated $23.4M.

  • 260 institutional investors held Myriad Genetics (MYGN) as of Q1 2018, up from 250 in Q4 2017.
  • Funds reported $2.22B of Myriad Genetics stock for Q1 2018, down 13% quarter-over-quarter.
  • 36 funds opened new Myriad Genetics positions in Q1 2018 and 23 closed out, a net change of +13 holders.
  • The largest Myriad Genetics buyer in Q1 2018 was Goldman Sachs, an estimated $25M added.
  • The largest Myriad Genetics seller in Q1 2018 was Wells Fargo, an estimated $23.4M sold.

Based on aggregated 13F filings for Q1 2018.